• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of stroke and cerebrovascular diseases: The official journal of National Stroke Association >The Therapeutic Effects of Endovascular Therapy with mTICI2b and 3 Recanalization for Acute Anterior Circulation Stroke Patients
【24h】

The Therapeutic Effects of Endovascular Therapy with mTICI2b and 3 Recanalization for Acute Anterior Circulation Stroke Patients

机译：血管疗法对急性前循环卒中患者血管血管治疗的治疗作用及3例急性前循环卒中患者

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background and Purpose: Modified Thrombolysis in Cerebral Infarction (mTICI)2b/3 has been considered the criterion for successful reperfusion in endovascular treatment. This study aimed to compare the therapeutic safety and efficacy of mTICI2b and mTICI3 recanalization, and to analyze the factors related to outcomes in everyday clinical practice. Materials and Methods: This is a single-center retrospective analysis of 224 patients who underwent successful thrombectomy (achieving a mTICI score >= 2b). The primary outcomes included a modified Rankin score (mRS) of 0-2 at 90-day, mortality, and symptomatic intracranial hemorrhage. Results: A total of 111 patients achieved mTICI2b status (49.6%), and 113 achieved mTICI3 status (50.4%). The comparison between mTICI2b and 3 reperfusions showed no differences in short-term outcomes, 90-day mRS, complications, and mortality. There was a trend toward more passes in mTICI2b patients, although the difference was not significant. The univariate analysis showed that poor outcomes after endovascular treatment were associated with older age, previous history of coronary heart disease, atrial fibrillation, diabetes, tandem occlusions, high National Institutes of Health Stroke Scale (NIHSS) score on admission, and general anesthesia. A previous history of coronary heart disease, a high NIHSS score on admission, and the use of general anesthesia were independent factors that affected the therapeutic effects. Conclusion: The superiority (efficacy and safety) of mTICI3 reperfusion was not significant compared with that of mTICI2b reperfusion. Prolonged efforts to achieve mTICI3 after achieving mTICI2b should be considered prudently for those with difficulty achieving 100% reperfusion.
机译：背景与目的：改良脑梗死溶栓（mTICI）2b/3被认为是血管内治疗成功再灌注的标准。本研究旨在比较mTICI2b和mTICI3再通治疗的安全性和有效性，并分析与日常临床实践结果相关的因素。材料和方法：这是一项单中心回顾性分析，共有224名患者接受了成功的血栓切除术（mTICI评分>=2b）。主要结果包括90天时改良Rankin评分（mRS）为0-2、死亡率和症状性颅内出血。结果：共有111名患者达到mTICI2b状态（49.6%），113名患者达到mTICI3状态（50.4%）。mTICI2b和3次再灌注之间的比较显示，短期结果、90天mRS、并发症和死亡率没有差异。mTICI2b患者有更多通过的趋势，尽管差异不显著。单变量分析显示，血管内治疗后的不良预后与年龄较大、既往冠心病史、房颤、糖尿病、串联闭塞、美国国立卫生研究院卒中量表（NIHSS）入院评分和全身麻醉有关。既往冠心病病史、入院时NIHSS评分高以及使用全身麻醉是影响治疗效果的独立因素。结论：与mTICI2b再灌注相比，mTICI3再灌注的优越性（有效性和安全性）不显著。对于难以达到100%再灌注的患者，应谨慎考虑在达到mTICI2b后延长达到mTICI3的时间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号